Market Place
Sourcing Support
Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics
27 Feb 2024 //
BUSINESSWIRE
Sorrento Announces the Consummation of Sale of Substantially of Common Shares
22 Sep 2023 //
PR NEWSWIRE
Sorrento goes to China with Covid drug; Vistagen touts data on PMDD nasal spray
13 Sep 2023 //
ENDPTS
Sorrento Announces PIII Trial Met Endpoint in COVID-19 Treated with Ovydso
12 Sep 2023 //
GLOBENEWSWIRE
Sorrento Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin
07 Sep 2023 //
GLOBENEWSWIRE
Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities
08 Aug 2023 //
PR NEWSWIRE
Sorrento Issues a FAQ in Response to Requests from Scilex Dividend Short Holders
27 Jul 2023 //
GLOBENEWSWIRE
Sorrento Announces Launch of Voluntary Offering to Dividend Short Holders
21 Jul 2023 //
PR NEWSWIRE
Sorrento Announces Positive Phase IIa Study Results of Abivertinib
05 Jul 2023 //
GLOBENEWSWIRE
Sorrento Announces the Full Enrollment of the Phase 3 Trial with Olgotrelvir
26 Jun 2023 //
GLOBENEWSWIRE
Sorrento announces a $4.6 Million U.S. Government contract from the NIAID
13 Jun 2023 //
GLOBENEWSWIRE
Sorrento Therapeutics, Inc.`s Bankruptcy Court Extends the Lockup Period
25 Apr 2023 //
PR NEWSWIRE
Scilex Announces that its Majority Stockholder, Sorrento Therapeutics
25 Apr 2023 //
GLOBENEWSWIRE
Sorrento`s Bankruptcy Court Requires Brokerages to Provide Information Related to Scilex Common Stock
04 Apr 2023 //
PR NEWSWIRE
Sorrento Receives Final Court Approval for $75M Debtor-In-Possession Financing
29 Mar 2023 //
PR NEWSWIRE
Court Confirms Sorrento`s $125 Million Arbitration Award Against NantPharma
17 Mar 2023 //
PR NEWSWIRE
G1 sheds staff while Sorrento WARNs of layoffs
02 Mar 2023 //
FIERCE BIOTECH
Sorrento Receives Court Approval for $75 Million Financing in Chapter 11 Case
21 Feb 2023 //
PR NEWSWIRE
Sorrento Issues Update to Issued FAQ Regarding Dividend of Scilex Common Stock
17 Feb 2023 //
GLOBENEWSWIRE
Sorrento Therapeutics Receives Court Approval for "First Day" Employee Wages
16 Feb 2023 //
PR NEWSWIRE
Embattled Sorrento files for bankruptcy amid ongoing legal fight
14 Feb 2023 //
FIERCE BIOTECH
Joint Statement by Sorrento & Scilex Holding on Isolated Chapter 11 Filing
13 Feb 2023 //
GLOBENEWSWIRE
Scilex Holding acquires rights to FDA-Approved ELYXYB in the U.S. and Canada
12 Feb 2023 //
GLOBENEWSWIRE
Sorrento Announces Record and Meeting Dates for Annual Meeting of Stockholders
04 Feb 2023 //
GLOBENEWSWIRE
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms
03 Feb 2023 //
GLOBENEWSWIRE
Sorrento Therapeutics has Issued a Supplement to its Previously Issued FAQ
02 Feb 2023 //
GLOBENEWSWIRE
Sorrento Issues Supplement to its Previously Issued FAQ Regarding the Dividend of Scilex Common Stock
02 Feb 2023 //
GLOBENEWSWIRE
Sorrento has Issued an FAQ Regarding Dividend of Scilex Holding Common Stock
29 Jan 2023 //
GLOBENEWSWIRE
Sorrento Issues FAQ Regarding Dividend of Scilex Holding Company Common Stock
29 Jan 2023 //
GLOBENEWSWIRE
Scilex Holding & Vickers Announce the Closing of Announced Business Combination
10 Jan 2023 //
PRESS RELEASE
Sorrento shows Positive Results from Ph1b & is Ready for PIII trials with OVYDSO
09 Jan 2023 //
GLOBENEWSWIRE
ImmunityBio looks to pull in $157M from Patrick Soon-Shiong and investor
12 Dec 2022 //
ENDPTS
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials
06 Dec 2022 //
GLOBENEWSWIRE
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint IMC-001
05 Dec 2022 //
GLOBENEWSWIRE
Arbitrator awards $157M to Soon-Shiong`s ImmunityBio in dispute with Sorrento
05 Dec 2022 //
ENDPTS
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Improvements
14 Nov 2022 //
GLOBENEWSWIRE
4P Conducts Ph 1b Study for Sorrento on Lymphatic Etanercept Delivery
26 Oct 2022 //
ACCESSWIRE
Sorrento Successfully Completes Phase 1 Study STI-1558
17 Oct 2022 //
GLOBENEWSWIRE
Sorrento Announces Publication of Data in Cell Press Journal Med
14 Oct 2022 //
GLOBENEWSWIRE
Sorrento Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin
26 Sep 2022 //
GLOBENEWSWIRE
Sorrento Announces the Publication in the Nature Journal Scientific Report
15 Sep 2022 //
GLOBENEWSWIRE
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual GHC Sep 12-14
08 Sep 2022 //
GLOBENEWSWIRE
Sorrento Announces Trial Results as Assessed by an IRC of Abivertinib
23 Aug 2022 //
GLOBENEWSWIRE
Sorrento Therapeutics Announces China NMPA IND Clearance of STI-1558
19 Aug 2022 //
GLOBENEWSWIRE
Scilex Announces Expanding Coverage With One Of The Largest PBMs For ZTlido
16 Aug 2022 //
GLOBENEWSWIRE
Sorrento Completes SAD Study and Initiates MAD Phase 1 Study with STI-1558
03 Aug 2022 //
GLOBENEWSWIRE
Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558
19 Jul 2022 //
GLOBENEWSWIRE
Scilex Holding Company Has Entered A Term Sheet to Acquire Ancora Medical Inc.
07 Jul 2022 //
GLOBENEWSWIRE
Scilex Holding Company appoints Tommy G. Thompson as Board of Directors
05 Jul 2022 //
GLOBENEWSWIRE
Scilex sues Apotex to block generic copy of key pain patch
28 Jun 2022 //
FIERCEPHARMA
Sorrento appoints Tommy G. Thompson, as Covid-19 Special Consultant
24 Jun 2022 //
GLOBENEWSWIRE
Scilex Holding Co. enters into excl. licensing agreement with ROMEG Therapeutics
14 Jun 2022 //
GLOBENEWSWIRE
Sorrento Announces First Subject Dosed in a PI Study of STI-1558
03 Jun 2022 //
GLOBENEWSWIRE
Scilex Holding Announces Pre-Emptive Repurchase of $41.4M of Senior Secured Note
03 Jun 2022 //
GLOBENEWSWIRE
Scilex Holding Company announces continued growth in ZTlido
02 Jun 2022 //
GLOBENEWSWIRE
Sichuan Kelun-Biotech, Levena are to Present Positive Clinical Progress of A166
01 Jun 2022 //
GLOBENEWSWIRE
Sorrento Announces FDA Authorization to Proceed With PII Study of Abivertinib
17 May 2022 //
GLOBENEWSWIRE
Lee`s Pharm Announces Enrollment of 498 Patients in PIII Trial of Socazolimab
17 May 2022 //
GLOBENEWSWIRE
Scilex Holding announced today the filing of Registration Statement on Form S-4
16 May 2022 //
GLOBENEWSWIRE
Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104
11 May 2022 //
GLOBENEWSWIRE
